Cirrhosis

Cirrhosis is a condition in which the liver slowly deteriorates and malfunctions due to chronic injury. Scar tissue replaces healthy liver tissue, partially blocking the flow of blood through the liver.

What is Cirrhosis?

Cirrhosis is a severe form of liver disease wherein normal liver tissue is replaced by scar tissue (fibrous tissue).

Managing and Treating Cirrhosis

What Causes Cirrhosis?

Liver Disease Symptoms

WHO report shows measurable progress in reducing global hepatitis infections

Global efforts to combat viral hepatitis are delivering measurable progress in reducing infections and deaths, but the disease remains a major global health challenge, according to a new World Health Organization (WHO) report released today at the World Hepatitis Summit.

28 Apr 2026

Engineered gut bacteria successfully treat metabolic drivers of liver disease

When the liver fails, toxins - such as ammonia - that should be filtered from the blood build up and reach the brain.

28 Apr 2026

Biliary epithelial cells found to actively prevent liver fibrosis development

Many liver diseases share a common characteristic: fibrosis, that is, the progressive accumulation of scarring in the liver tissue.

28 Apr 2026

Delaying hepatitis B birth vaccines increases infant infection risks

Delaying hepatitis B vaccination after birth increases infections among newborns and decreases their survival rates and quality of life, according to a new Cornell University study.

27 Apr 2026

Study identifies key risk factors driving MASLD across populations

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 32% of the US adult population.

23 Apr 2026

Specific intestinal fungi play role in the pathogenesis of MASLD and cardiovascular disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an independent risk factor for cardiovascular disease (CVD). While gut bacteria have been linked to CVD, the role of intestinal fungi in subclinical coronary atherosclerosis (SCA) remains unclear.

23 Apr 2026

AGA update calls for better surveillance of hepatocellular carcinoma

A new update from the American Gastroenterological Association (AGA) urges stronger prevention efforts and better early-detection tools for hepatocellular carcinoma (HCC), the leading cause of cancer-related death in patients with cirrhosis, and the third most common cause of cancer-related death worldwide.

17 Apr 2026

Gut-liver changes drive foodborne infection severity in fatty liver disease

A research team led by the University of California, Irvine's Joe C. Wen School of Population & Public Health has uncovered a critical biological link explaining why individuals with metabolic dysfunction–associated steatotic liver disease (MASLD), or fatty liver disease, face significantly worse outcomes from certain foodborne infections.

15 Apr 2026

Semaglutide improves liver function independently of weight loss

Researchers at Toronto's Sinai Health have found that semaglutide – the active ingredient in popular weight loss drugs that mimic the gut hormone GLP-1 – acts directly on a subset of liver cells to improve organ function and does so independently of weight loss.

15 Apr 2026

Liver cancer burden rising globally amid shift to metabolic risks

Primary liver cancer continues to pose a major global health challenge, ranking as the third leading cause of cancer-related deaths worldwide.

15 Apr 2026

Hepatologists effectively deliver palliative care to patients with liver disease

Advanced liver disease (ALD) occurs when significant scarring causes the liver to lose function. Patients with ALD often have serious health challenges but have limited access to palliative care that could improve their quality of life.

13 Apr 2026

Ultrasound advances offer noninvasive assessment of portal hypertension severity

Portal hypertension (PH), a serious complication of liver cirrhosis, is defined as a pressure gradient > 5 mmHg between the portal vein and the inferior vena cava.

27 Mar 2026

Machine learning model predicts liver cancer risk with high accuracy

A machine learning model that analyzes patient demographics, electronic health record data, and routine blood test results predicted a patient's risk of hepatocellular carcinoma (HCC), the most common type of liver cancer, with high accuracy.

26 Mar 2026

New algorithm enables precise subtyping of metabolic liver disease

Metabolic-associated steatotic liver disease (MASLD) is a clinically heterogeneous condition with highly variable outcomes affecting more than 30% individuals globally.

26 Mar 2026

Palmatine improved fatty liver markers in a preclinical type 2 diabetes study

Researchers used a bioinformatics-plus-rat-model approach to investigate how palmatine may help treat T2DM-associated MASLD, identifying five core targets: ADRB2, BCL3, EGR1, FOS, and MAP3K8. In rats, palmatine improved liver injury, inflammation, oxidative stress, glycolipid metabolism, steatosis, and fibrosis, while reducing apoptosis-related signaling, providing a preclinical foundation for further therapeutic study.

23 Mar 2026

Expert consensus validates UDFF for noninvasive fatty liver assessment

As the global burden of obesity, type 2 diabetes, and metabolic syndrome continues to rise, fatty liver disease has become one of the most prevalent chronic liver conditions worldwide. Its progressive forms, including metabolic dysfunction‐associated steatohepatitis (MASH), cirrhosis, and hepatocellular carcinoma, now represent a major public health challenge.

17 Mar 2026

EVA1A regulates fatty acid transporter CD36 in fatty liver disease

Metabolic Dysfunction-Associated Steatotic Liver Disease（MASLD） is characterized by excessive accumulation of lipids in hepatocytes and is closely associated with the rapid rise in insulin resistance, obesity, and diabetes prevalence, making it one of the most common chronic liver diseases worldwide.

9 Mar 2026

Protein aggregates in the liver may protect against alcohol-induced damage

Alcohol-associated liver disease (ALD) remains a leading cause of cirrhosis and liver-related mortality worldwide, with few effective therapies.

9 Mar 2026

Women face higher liver fibrosis risk from cardiometabolic factors than men

Women with certain cardiometabolic risk factors, including type 2 diabetes and high waist circumference, face a greater increase in risk for liver fibrosis than men with the same risk factors.

9 Mar 2026

New fragmentome technology can detect early liver fibrosis and cirrhosis

Researchers at the Johns Hopkins Kimmel Cancer Center report that an artificial intelligence (AI)-based liquid biopsy test using genome-wide cell-free DNA (cfDNA) fragmentation patterns and repeat landscapes can detect early liver fibrosis and cirrhosis, and may also reveal signals of broader chronic disease burden.

4 Mar 2026